Why the study?
Does pioglitazone improve histological response and adipose tissue insulin resistance in patients with nonalcoholic steatohepatitis?
Does pioglitazone improve histological response and adipose tissue insulin resistance in patients with nonalcoholic steatohepatitis?
Pioglitazone-induced improvement in adipose tissue insulin resistance correlates with histological improvement in patients with NASH.
Pioglitazone may be prioritized in NASH to target Adipo-IR for histology gains; extends RCT mechanistic evidence.
Patients with NASH have severe Adipo-IR independent of the degree of obesity. Amelioration of Adipo-IR by pioglitazone is closely related to histological improvement and plays an important role during treatment of patients with NASH.
No takes yet. Share an insight, caveat, or question.
Gastaldelli et al. (2009) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: